Onco-Summaries: Daily Oncology Updates at a Glance
08/09/2026
Imfinzi + Imdelltra demonstrated significant benefit in 1st‑line ES‑SCLC maintenance (Ref)
AstraZeneca reported positive interim results from the Phase 3 DeLLphi‑305 trial, showing that Imfinzi (durvalumab; anti‑PD‑L1) + Imdelltra (tarlatamab; DLL3 x CD3 bispecific T‑cell engager) significantly improved overall survival (OS) compared to Imfinzi alone in patients with extensive‑stage small cell lung cancer (ES‑SCLC) who had not progressed after induction therapy with Imfinzi + platinum chemotherapy (carboplatin or cisplatin) + etoposide
In addition, a statistically significant and clinically meaningful improvement in the secondary endpoints of progression-free survival (PFS) and objective response rate was also observed
Safety and tolerability profile of Imfinzi + tarlatamab was consistent with the known safety profiles of the individual treatments, with no new safety signals identified
Detailed results will be presented at a forthcoming medical meeting and shared with global regulatory authorities
In registrational Phase 2 QUINTESSENTIAL trial, GPRC5D CAR T therapy (arlo‑cel) achieved significant ORR improvement in heavily pretreated multiple myeloma (Ref)
Bristol Myers Squibb announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo‑cel; BMS‑986393), a potential first‑in‑class GPRC5D‑directed CAR T cell therapy in relapsed/refractory multiple myeloma
Trial met its primary endpoint with a statistically significant and clinically meaningful overall response rate (ORR) and secondary endpoint of complete response rate (CRR) in patients with ≥4 prior lines of therapy
The safety profile of arlo-cel was consistent with that of other CAR T cell therapies and other GPRC5D-targeting therapies in multiple myeloma
Detailed results from QUINTESSENTIAL will be presented at an upcoming medical meeting
INBRX‑106 + pembrolizumab elicited strong ORR signal in Phase 2 part of Ph2/3 HexAgon-HN trial, driving expansion and FDA‑aligned path to Phase 3 confirmatory trial in HNSCC (Ref)
Inhibrx announced positive interim results from the Phase 2 part of the Ph2/3 HexAgon-HN trial evaluating Inhibrx & Elpiscience’s INBRX-106 (anti-OX40) + pembrolizumab (anti-PD-1) vs pembrolizumab monotherapy as first-line treatment in patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)
In 63 pts who were evaluable for the primary endpoint analysis, confirmed objective response rate (cORR) was 48.3% with INBRX‑106 + pembrolizumab vs 26.5% with pembrolizumab alone
Complete responses: 13.8% vs 0.0%
Median PFS: 9.6 months vs 4.9 months; 6‑month PFS rates 72.4% vs 42.8%
Improved efficacy signal was particularly observed I HPV+ subgroup of pts
cORR: 80% vs 33.3%,
Complete response 30% vs 0.0%
MPFS: NR vs 4.6 months; 6-month PFS rates: 90% vs 33%
The combination of INBRX-106 and pembrolizumab was well tolerated. The most common TRAEs were rash, fatigue, and diarrhea, which were predominantly low grade
Inhibrx plans to expand the randomized Phase 2 portion of the HexAgon trial by enrolling ~50 additional HPV+ OPSCC patients (CPS ≥ 1) to strengthen the data for a potential accelerated regulatory pathway
Following the Phase 2 expansion, the Company plans to align with the FDA on this framework and initiate the Phase 3 portion of the HexAgon-HN trial, which is intended to serve as the confirmatory study
Comments